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Introduction
For more than 30 years, the standard approach to adjuvant treatment of oestrogen receptor-positive early-stage breast cancer in postmenopausal women was to treat patients with up to 5 years of tamoxifen. Tamoxifen has been shown to be very effective and to reduce breast cancer-related mortality by up to 50% [1] . With the third-generation aromatase inhibitors, an even more effective substance class was introduced as therapeutic alternative [2] [3] [4] [5] [6] [7] . Hence, international guidelines state that optimal adjuvant hormonal therapy for a postmenopausal woman with receptor-positive breast cancer should include an aromatase inhibitor, either as initial therapy or after treatment with tamoxifen [8] . Also German guidelines acknowledge the superiority of third-generation aromatase inhibitors compared to tamoxifen for assured postmenopausal woman with early-stage breast cancer [9] . One of the possible treatment strategies emerging from these guidelines and advances in daily clinical practice is to initially treat patients with tamoxifen for the first 2-3 years and then to switch to alternative treatments such as exemestane. The objective of this model is to assess the costs and health outcomes of continuing to use adjuvant tamoxifen therapy for a further 2-3 years compared with switching to adjuvant treatment with exemestane at 2-3 years, in the German health care context.
Patients and Methods

A Markov model was developed in Microsoft Excel
® to assess the cost effectiveness of exemestane relative to continued tamoxifen as adjuvant therapy for early-stage breast cancer. Cost and health outcomes were assessed in terms of the incremental cost per life year gained, the incremental cost per quality-adjusted life year (QALY) gained, or the incremental cost per disease-free life year gained. The latter outcome demonstrates the treatment impact on surrogate markers that determine whether treatment is a success or a failure.
Model Structure
This model takes the perspective of the German Statutory Health Insurance (SHI). It is difficult to collect data showing the productivity loss associated with early-stage breast cancer or its treatment. A true measurement is likely to show that such costs are relatively small, due to the age of the population. The model therefore only considers health care-related costs.
The model uses the following health states to demonstrate differences between the different treatment arms in the model: -no recurrence of breast cancer -remission from breast cancer -local recurrence of breast cancer -distant recurrence of breast cancer -contra-lateral breast cancer -death from breast cancer -death from other causes Osteoporosis, endometrial cancer and thromboembolism (pulmonary embolism (PE) and deep-vein thrombosis (DVT)) are incorporated into the model as adverse events using separate health states. Osteoporosis is included by replicating all of the health states listed above (osteoporosis with no recurrence, osteoporosis with disease remission, osteoporosis with local recurrence, osteoporosis with distant recurrence, osteoporosis with contra-lateral breast cancer). Once a patient is diagnosed with osteoporosis, she stays in an osteoporosis-related state but can still transition between different health states in the same way as patients without osteoporosis.
Endometrial cancer is incorporated in a manner different to osteoporosis. It is assumed that endometrial cancer 'dominates' other states in the model, so that patients can only remain in the endometrial cancer health state or move to death. This assumption is based on discussions with clinical experts. Thromboembolism is included as a reversible event with a separate health state. Patients are able to move to breast cancerrelated health states once the thromboembolism has resolved. Cost Effectiveness of Exemestane 391
Other adverse events are also included in the model. The impacts of vaginal haemorrhage, cardiac failure, myocardial ischaemia, arthralgia, and hypertension on health care costs are incorporated into the model as event tolls. These events were deemed either too rare to justify a separate health state, or clinical advice stated that the impact on quality of life was likely to be minimal. The general structure of the model and its allowable transitions are displayed in figure 1.
Allowable transitions from two adverse events -osteoporosis and thromboembolism -are shown in the separate diagrams of figures 2 and 3. Osteoporosis is a permanent condition in the model, but one that operates independently of breast cancer. That is, a patient with osteoporosis will have osteoporosis for the rest of her life, but the breast cancer will progress at the same rate as if a patient did not have osteoporosis.
Thromboembolism is also incorporated into the model. It is assumed that the episode is successfully treated, after which patients either remain in the post-thrombolytic state (equivalent to no recurrence) or transition to one of the other states that those in the no-recurrence health state are able to move to (as shown in fig. 1 ).
The population included in the model reflects the study data of the Intergroup Exemestane Study (IES) [10] . Hence, the cohort in the model consists of postmenopausal women with a median age of 63 years (range 31-96 years) who had already spent an average 28 German age-specific mortality data [11] na = Not applicable. The time horizon for the cohort was lifetime (maximum 38 years from a starting age of 63). German age-specific mortality data [11] were used to incorporate death from other causes. Finally, a cycle length of 6 months was chosen for the model as reasonable assumption for the time taken to transition between the health states according to clinical experts. A halfcycle correction was employed to take into account the fact that events occur during the cycle period and not only at the end of a cycle.
The model calculates the average cost and outcome on a per patient basis. With this, incremental cost effectiveness ratios can be calculated. The average costs per treatment arm over the duration of the model are calculated as the sum of the cycle costs on each arm. Costs and outcomes occurring after the first year are discounted with 5% per annum, as recommended by the third and updated version of the Hanover Consensus, which is the current guideline for health economic evaluation in Germany [12] .
Clinical Data
The utilities attached to the different health states and adverse events used in the model are shown in table 1. International data had to be incorporated as no German-specific utilities were available for this context. The model also includes a probabilistic sensitivity analysis. In this way, the impact of variation due to uncertainty around the key parameters (transition probabilities, costs and utilities) on the baseline cost effectiveness results can be assessed. Probabilistic cost effectiveness results are obtained using 1000 Monte Carlo simulations.
The transition probabilities used in the first 36 months of the model are displayed in table 2. These transition probabilities are taken from the results of the IES trial and represent the probability of moving from one health state to another. However, it is important to consider the probabilities used beyond the 36-month follow-up of the pivotal trial. In order to be conservative, it was assumed that exemestane and tamoxifen would have the same effect in preventing recurrences after the end of the follow-up period, despite the fact that exemestane patients showed fewer recurrences over the 36-month follow-up period. This is a conservative assumption that will increase the value of the incremental cost effectiveness ratio.
The data used to estimate the transition probabilities after the end of the trial follow-up were based on three key publications. First, the probabilities of progressing from no recurrence to local recurrence, distant recurrence and contra-lateral disease were based on 15-year survival data for tamoxifen [1] . Firstly, this data tracks the progression of breast cancer patients over time and provides a strong source for estimating transition probabilities that are needed over the long time period. Secondly, the probability of remaining in the distant-recurrence health state is derived from a key observational study [21] . These results showed that median survival is 21 months among metastatic breast cancer patients, tracking the survival of metastatic breast cancer patients over the medium term. A third key source was used to estimate the probability of progressing from local recurrence to distant recurrence [22] . The results of that study showed that 41% of the patients progressed from local breast cancer to distant-stage breast cancer over a 5-year period. Overall, 6-month probabilities for each of these transitions were calculated based on these results.
Resource Use and Unit Costs
The model parameters were mainly identified on the basis of the DRG Browser [23] for inpatient costs, the EBM 2000 plus [24] (official remuneration within the SHI for outpatient services), and current market prices for drugs [25] . With the assistance of medical experts, the appropriate diagnosis-related groups (DRGs) were identified. Braun/Mittendorf/Menschik/Greiner/ von der Schulenburg pound was not included in the fixed-price catalogue, the price of the cheapest product was taken (table 3) . The costs for an osteoporosis fracture are calculated with a weighted average based on the real-life frequency of the relevant DRGs. A thromboembolism is divided into several episodes. The costs of the first episode are divided depending on the local occurrence of embolism in the body. In this context PE and DVT are relevant, which by assumption occur at 50% each. Costs for maintenance therapy within the first model cycle after occurrence include 12 general practitioner (GP) visits, 12 blood tests and a daily dosage of 5 mg warfarin. In the following cycles of up to 3 years, the number of GP visits and blood tests is reduced to 3 each and the warfarin medication remains stable. Costs for diagnosing an endometrium carcinoma were assessed accordingly, with 3201 Euro making up for the first 6 months of chemotherapy.
Inpatient costs for treating breast cancer do also result from a weighted DRG average adding the same costs for chemotherapy as mentioned above. In non-responders, the therapy stops after 3 months. Hence, for non-responders 6-month cycle costs are half for chemotherapy. Direct medical costs for 14 days of terminal care result from home care or nursing home stays (44%) and inpatient or hospice stays (56%), respectively. The costs for routine care are the result of 2 home visits as well as 4 GP outpatient visits per year.
Finally, the costs for the 5 included therapy-related adverse events (cardiac failure, hypertension, athralgia, vaginal haemorrhage, myocardial ischaemia) were calculated as described for the other events, with physician services being based on the EBM and costs for drugs taken from the Red Book.
Results
The time spent in each health state is displayed in table 4. These results indicate that, over the model period, exemestane patients spend 0.71 more years in a no-recurrence health state than tamoxifen patients (although much of this is spent with osteoporosis). On the other hand, tamoxifen patients spend more time in local and distant recurrence, remission following recurrence, discontinuation of treatment due to an adverse event, and death. As tamoxifen patients spend more time in health states with poorer quality of life, this is likely to lead to improved overall health outcomes in the exemestane arm. The baseline results for the incremental cost per QALY gained with exemestane vs. tamoxifen are shown in may be a cost-effective alternative adjuvant therapy in breast cancer. As shown by the results of the disaggregated cost and outcome analyses, exemestane is only slightly more expensive than tamoxifen over the model period, and has a clear gain in health outcomes. It is these two factors that drive the cost effectiveness result. While the incremental cost per QALY gained is generally the key result for decision makers, it is also important to measure alternatives. Life years and disease-free years are useful measures of the effectiveness of cancer treatment. Hence, baseline results for the incremental cost per life year and per disease-free year gained with exemestane versus tamoxifen are also presented in table 5.
The cost effectiveness acceptability curve ( fig. 4 ) comes as a result of the probabilistic sensitivity analysis. It represents the likelihood that each treatment is cost effective at various willingness-to-pay thresholds. Hence, exemestane would be cost effective in over 80% of all cases at a relatively low threshold of 25,000 Euro per additional QALY.
Discussion
Up to now no evidence has been published regarding the cost effectiveness of exemestane in the German treatment setting. Hence, no comparison of the findings of this study with existing evidence is possible. However, internationally there exist three other published Markov models incorporating clinical data at least partly based on the results of the IES study [26] [27] [28] . The structures of those models as well as the findings are quite similar to the results of this modelling approach. Each study looked at the cost effectiveness in specific health care settings (Sweden and the USA), making it difficult to transfer them one by one to the German health care setting. With that in mind, the present study gives a detailed glimpse into the very specific setting of the German SHI. In future regulatory processes, the German Institute for Quality and Efficiency in Health Care (IQWiG) will play a major role by not only assessing benefits of novel treatment regimens but also looking at the cost benefit ratios. This paper could inform early discussions with such regulatory agencies in Germany, helping to optimise treatment not only from a clinical but also a health economic standpoint.
There are three main areas where our data is lacking information or can be improved:
Firstly, the clinical data input does not completely comprise the findings from clinical trials. This has led to certain assumptions in some domains being made on the basis of expert opinions. In particular, there is some missing information around each of the adverse events included in the model which could not be obtained from the literature. However, this limitation is quite common to a modelling approach like this and was addressed by conducting extensive sensitivity analyses reflecting the uncertainty around those parameters.
Secondly, there are a number of published studies that report utilities for health states equal or similar to those included in the model. Those different references could be combined in forming clinical data input into the model. However, no study could be found that included utilities for all of the health states used in the model. It would always be preferable to use as few sources as possible for the assessment of utility values, as the population used to elicit utilities has a key role in the absolute and relative utilities. Hence, the same utility values have been assigned to patients under exemestane and tamoxifen therapy, as there is no published information on differences between these two alternatives. This of course might be considered as being a more conservative as well as an optimistic reflection of treatment reality. Also, the utility values associated with recurrence of breast cancer were used as a proxy for contra-lateral breast cancer utility values, leaving a chance of under-or overestimating this estimate.
Lastly, although treatment guidelines are available for early-stage breast cancer, they are not explicit in detailing which health care pathways or regimens should exactly be used to treat those patients. Again, this has led to assumptions based on expert opinions.
Conclusion
Overall, baseline results as well as results from the probabilistic sensitivity analysis suggest that exemestane is likely to be a cost-effective alternative in comparison to tamoxifen for adjuvant therapy of early-stage breast cancer in the German health care setting.
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